Progression of cells into S phase is controlled by the retinoblastoma protein (pRB) and relies on the functional inactivation of this tumour suppressor in late G1 via protein phosphorylation. We provide evidence here that, besides controlling entry of cells into S phase, pRB can operate to inhibit S phase completion. Dierential arrays of phosphorylation appear to regulate these dierent events, suggesting that cycle progression at these two stages of the cell cycle may be achieved via activation of distinct downstream pRB eector pathways. In agreement with this hypothesis, pRB's ability to prevent S phase entry, but not its ability to inhibit S phase completion, correlates with repression of E2F-regulated promoters. Furthermore, ectopic expression of E2F or the E2F-regulated cyclin E gene promote S phase entry in cells expressing phosphorylation-defective pRB but neither is sucient to trigger completion of S phase. Our ®ndings raise the possibility that pRB, in addition to its well-established role in controlling a checkpoint in late G1, could be involved in the control of a further checkpoint operating during S phase and that implementation of this checkpoint relies on an as yet unidenti®ed pRB eector distinct from E2F.
Introduction
The growth-controlling activity of the tumour suppressor, retinoblastoma protein (pRB), relies on its capacity to reversibly associate with E2F and other cellular transcription factors (Herwig and Strauss, 1997; Weinberg, 1995) . The phosphorylation state of pRB determines its ability to bind to these factors (reviewed in Bandara et al., 1993; Taya, 1997) . Evidence to this eect was ®rst provided through analysis of pRB's association with SV40 T antigen (Sterner et al., 1998; Templeton et al., 1991; Whyte et al., 1989) . Only un-or poorly phosphorylated pRB associated with this viral oncoprotein and this has since been similarly demonstrated for many of the cellular pRB ligands.
Phosphorylation of pRB, leading to its inactivation, is executed by members of the cyclin-dependent family of protein kinases (ConnellCrowley et al., 1997; Johnson et al., 1995; Lees et al., 1991; Lin et al., 1991; Mittnacht et al., 1994; Sterner et al., 1998; Templeton et al., 1991; Whyte et al., 1989; . In growing cells, the phosphorylation state of pRB changes periodically and in accordance with the cellular division cycle. Un-or poorly phosphorylated pRB, distinguished from its highly phosphorylated variant by a faster migration in SDS gels and its tight association with the cell nucleus, exists in cells only during the early phases of G1 (Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989; Mittnacht et al., 1991 Mittnacht et al., , 1994 . This form of pRB is no longer detectable upon passage of cells into S phase. Instead, highly phosphorylated pRB accumulates and prevails throughout the remainder of the cell cycle until the cells enter the next G1 phase, when pRB is converted into an un-or poorly phosphorylated form by dephosphorylation (Ludlow et al., 1990; Mittnacht et al., 1991) . These observations suggested a model whereby pRB controls a checkpoint in G1, the passage of which depends on pRB's phosphorylation, this resulting in a loss of its transcription factorbinding ability, and consequently, the transcription of genes whose products are required for further cell cycle progression.
Other observations, however, argue that such a model does not adequately describe the role of pRB in regulating cell cycle progression. There are 16 consensus sites for cyclin-dependent kinase phosphorylation in the human pRB sequence, 15 of which are conserved in rodent and human pRB. It is not clear whether pRB becomes phosphorylated on all these sites but evidence has been provided that dierentially phosphorylated forms of pRB exist in cells (DeCaprio et al., 1992; Mittnacht et al., 1994) . Intriguingly, dierent subsets of sites appear to regulate pRB's association with dierent types of ligands (Knudsen and Wang, 1996) . Furthermore, dierent cyclindependent kinases appear to phosphorylate pRB dierentially (ConnellCrowley et al., 1997; DelSal et al., 1996; Hurford et al., 1997; Kitagawa et al., 1996; Lundberg and Weinberg, 1998; . Moreover, alterations in the array of phosphorylation occur even after cells have passed the G1/S transition (DeCaprio et al., 1989) . Taken together, these observations indicate that changes of pRB's activity occur at positions other than G1/S and that phosphorylation by dierent kinases may have dierential eects on pRB's activity.
The contribution of individual phosphorylation events to the inactivation of pRB is controversial. It has been demonstrated that a version of mouse pRB in which 10 of the 15 consensus sites have been eliminated by mutation is constitutively active in that it eciently suppresses S phase entry when expressed in rodent and human cells (Knudsen and Wang, 1997; Lukas et al., 1997) . Which of these mutations are responsible for conferring constitutive activity has not been addressed in detail. Other work has demonstrated that pRB's ability to prevent S phase entry upon injection into pRB phosphorylation-incompetent SAOS-2 cells cannot be inactivated by prior cyclin E kinase phosphorylation and that its inactivation relies on phosphorylation of threonine 795 (T795) by cyclin D kinases. This points to a special role for this particular site in pRB inactivation (ConnellCrowley et al., 1997) . Yet other evidence would seem to suggest that mutation of T795 alone does not preclude pRB inactivation since expression of pRB lacking 8 phosphorylation sites, including T795, is unable to impair cell cycle progression in pRB phosphorylationcompetent cells (Alevizopoulos et al., 1997; Lukas et al., 1997) .
In an attempt to map in detail the sites that are involved in mediating pRB inactivation, we examined a panel of dierent phosphorylation site mutants for their eect on both long term proliferation and cell cycle progression in pRB phosphorylation-competent U2-OS cells. We provide evidence below that phosphorylation of carboxy-terminal sites is critical for pRB inactivation and, more importantly, that phosphorylation-defective pRB confers cell cycle arrest not only during G1 but also during S phase.
Results

Generation of phosphorylation-defective pRB mutants
To address which cdk phosphorylation sites are responsible for the inactivation of the growth suppressive function of pRB, we generated mutants in which consensus cdk phosphorylation sites were removed by exchanging the phosphate-accepting serines or threonines into non-phosphorylatable alanines. By sequentially mutating sites in the aminoterminus, the pocket spacer or the carboxy-terminus, we generated RB(N-), RB(P-) and RB(C-) and, by combining the respective mutated regions, created further mutants, including RB(NPC-), a pRB version in which 14 of the 15 conserved cdk consensus sites are eliminated ( Figure 1a) .
To ensure functionality of the various pRB mutants we performed two distinct types of assays. In order to assess synthesis and the ability of the pRB mutant proteins to become phosphorylated we transfected plasmid constructs encoding the various mutants into C33-A cells. This pRB negative cell line is readily transfectable and upon coexpression of pRB and a mixture of G1/S cyclins gives rise to the full spectrum of phosphorylated pRB species (Knudsen and Wang, 1997) . As can be seen in Figure 1b , all constructs, when assayed in this manner, resulted in expression and accumulation of protein products comparable in size to that of wt pRB. However, each of them displayed a dierent spectrum of retarded species, likely re¯ecting the dierential degree of phosphorylation achievable with these dierent mutants.
To examine whether the various mutant proteins were functional we transfected them into SAOS-2 cells. These cells are classically used an an assay system to assess pRB function (Hinds et al., 1992; Templeton et al., 1991) . Upon expression of functional pRB they cease proliferation arresting in the G1 phase of the cell cycle. We found that all mutant constructs when tested in this assay caused a substantial increase in G1 cells relative to vector transfected controls (Figure 1c ). We also note that transfection of all of them inhibited colony outgrowth and resulted in the appearance of single giant cells with¯at and irregular cell bodies, a morphology that characteristically is seen in SAOS-2 cells upon pRB expression (data not shown). Together the above experiments demonstrate that the undertaken mutagenesis-however substantial-did not aect synthesis and accumulation of the respective mutant proteins or destroy their ability to control proliferation of SAOS-2 cells.
Eect of phosphorylation-defective pRB mutants on cell proliferation
To determine whether the RB mutants were defective for inactivation we tested their ability to inhibit proliferation in U2-OS cells. Unlike SAOS2 cells, U2-OS cells are able to phosphorylate pRB and presumably because of this can tolerate pRB expression (Zhu et al., 1993) . Because of their ability to inactivate pRB via protein phosphorylation these cells should be a suitable system to score for pRB mutants that can no longer be inactivated via the cellular phosphorylation pathways.
In order to assess their capacity to block U2-OS cell proliferation we tested whether the various mutants would inhibit colony outgrowth upon transfection into these cells along with a puromycin resistance marker. We found that transfection of U2-OS cells with a plasmid directing the expression of wt pRB resulted in outgrowth of puromycin-resistant colonies with an eciency similar to vector-transfected control cells (Figure 2a ). In contrast, transfection of RB(NPC-), the pRB mutant lacking 14 phosphorylation sites, resulted in a dramatic reduction in colony numbers, a ®nding that is consistent with the notion that tolerance of U2-OS cells to pRB expression relies on the ability of these cells to phosphorylate this tumour suppressor (Figure 2a) . Moreover, single cells with enlarged and¯attened cell bodies arose in culture dishes transfected with this mutant (Figure 2b ) a morphology reminiscent to that seen in pRBphosphorylation incompetent SAOS-2 upon transfection with wt pRB. This indicates that expression of this phosphorylation-defective pRB not only restricts colony outgrowth in U2-OS cells but induces characteristic phenotype changes known to be associated with pRB function.
Also, RB(C-) reduced colony numbers signi®cantly and so did the mutants (NC-) and (PC-). Furthermore, and akin to RB(NPC-), expression of these mutants resulted in the appearance of cells with enlarged and at cell bodies ( Figure 2b and data not shown). Notably, neither RB(N-) nor RB(P-) showed these eects, while RB(NP-), a mutant lacking all but the sites in the carboxy-terminus, had only a mild impact on colony numbers. Furthermore, colonies that arose upon transfection with this mutant were indistinguishable in size and morphology from those of vector or wt pRB transfected cultures (see Figure 2b) . Notably, RB(C6-), a pRB version in which only six instead of seven carboxy-terminal sites were mutated, leaving S780 in its original form, was signi®cantly weakened in colony suppression and the induction of¯at cells.
We further note that T795, a site whose phosphorylation has previously been shown to be critical for inactivation has previously been shown to be critical for inactivation of pRB by cyclin D/cdk4 (ConnellCrowley et al., 1997) , is mutated in RB(C6-). This may indicate that inactivation of pRB in U2-OS cells can be achieved through phosphorylation by kinases other than cyclin D/cdk4.
Taken together, these results imply that inactivation of pRB's growth-inhibiting function in U2-OS cells may critically depend on phosphorylation of carboxyterminal sites, at least one of which appears to be S780. They also imply that phosphorylation of aminoterminal or pocket spacer sites is neither sucient nor necessary to inactivate pRB's ability to inhibit growth in U2-OS.
Cell cycle eects of pRB phosphorylation mutants
Existing evidence suggests that pRB controls cell proliferation by preventing the passage of cells through a checkpoint in late G1, thus hindering their entry into S phase. To investigate whether the colony reducing activity of phosphorylation-defective pRB relies on restricting passage of cells through this G1 checkpoint, we examined the cell cycle distribution of U2-OS cells transiently transfected with the various RB mutants (Figure 3 ). Expression of wt pRB had no apparent impact on the cell cycle distribution of U2-OS cells, consistent with its inability to inhibit colony outgrowth. In contrast, expression of RB(NPC-) signi®cantly increased the amount of cells with a 2n Figure 2 Colony forming ability of U2-OS osteosarcoma cells transfected with the pRB phosphorylation-defective mutants. U2-OS cells were transfected with the indicated pRB constructs, a plasmid encoding puromycin resistance and a plasmid encoding beta-galactosidase. Cells were split for 24 h post transfection and used for colony formation assay and for measurement of betagalactosidase activity. (a) Relative colony numbers obtained from the respective transfections. Colony counts were normalized to the beta galactosidase values obtained in the respective transfections and are presented in percent relative to wt pRB. Data are derived from at least three independent experiments. (b) Cell appearance upon transfection of selected mutants. Photographs were taken after puromycin selection and are derived from one representative experiment DNA content while reducing the amount of cells with 4n, thus presumably causing the transfected cells to arrest in G1. The amount of cells with a DNA content greater than 2n and less than 4n was also slightly increased. This was observed consistently and suggests that a portion of cells expressing RB(NPC-) may have entered S phase but failed to complete it. Both RB(N-) and RB(P-) had no obvious impact on the cell cycle pro®le, in keeping with their inability to inhibit colony outgrowth (see Figure 3a) . Unexpectedly, RB(C-), a construct that upon transfection into U2-OS cells inhibited colony outgrowth to nearly the same extent as RB(NPC-) (see Figure 2a) , did not seem to signi®cantly aect the cell cycle distribution of these cells. Although, there was a consistent slight decrease in the amount of 4n cells combined with an increase in cells with a DNA content greater than 2n and smaller than 4n.
The fact that RB(C-) has a signi®cant impact on cell cycle progression became apparent when the cells were treated with Nocodazole, a drug that prevents passage of cells through M phase. In the presence of this drug actively cycling cells will clear from the G1 and S compartments and accumulate in G2/M, whereas cells arrested prior to this cell cycle stage should stay behind. Under such modi®ed experimental conditions RB(C-) presented a cell cycle pro®le that was distinct from both vector transfected and the RB(NPC-) transfected cells (see Figure 3b ). The amount of 2n cells was evidently increased in comparison with vector transfections though to a lesser extent when compared with RB(NPC-). Instead, RB(C-) resulted in much more pronounced accumulation of cells with a DNA content greater than 2n and less than 4n. This ®nding provides further support for the notion that pRB may regulate cell cycle progression not only by controlling S phase entry but, in addition, by interfering with S phase completion. Moreover, the dierential ability of RB(NPC-) and RB(C-) to arrest cells in G1 and during S phase suggests that distinct subsets of phosphorylation sites may be responsible for regulating these two events. While phosphorylation of pRB on aminoterminal and/or pocket spacer sites seem sucient to trigger passage of cells into S phase, phosphorylation on carboxy-terminal sites seems essential to allow S phase completion. We note that, contrary to RB(C), RB(C6-) did not show an obvious cell cycle phenotype, signifying that phosphorylation of S780 may be sucient to inactivate pRB's S phase inhibiting powers.
In an attempt to locate more precisely the sites responsible for regulating G1/S transition as opposed to S phase completion we examined a set of combination mutants (Figure 3 ). We found that combined mutation of carboxy-terminal sites with those in the amino-terminus (RB(NC-)) or those in the pocket spacer (RB(PC-)) results in pRB mutants that were ecient in mediating G1 arrest. Combined ablation of amino-terminal and pocket spacer sites (RB(NP-)) had only a marginal eect. This indicates that phosphorylation of amino-terminal and pocket spacer sites may cooperate with sites in the carboxyterminus in the regulation of S phase entry and, furthermore, that phosphorylation of amino-terminus and pocket spacer sites may not be essential for cell cycle progression. To address whether the dual type of cell cycle arrest seen with our phosphorylation-defective pRB mutants was speci®c for pRB, we compared the cell cycle impact of RB(NPC-) with that of the cyclin-dependent kinases inhibitors p16 INK4 and p27 KIP , both known to cause arrest in G1 through inhibition of G1/S cyclindependent kinases. We found that, in contrast to RB(NPC-), these inhibitors resulted in a tight accumulation of cells in G1, combined with a net decrease in the S phase population (Figure 4) .
Eect of non-phosphorylatable pRB on S phase completion
So far, our experiments indicate that pRB may be able to regulate cell proliferation not only guarding the G1/S border but, in addition, by inhibiting progression of cells through S. However, all these experiments were based on the expression of phosphorylation-defective pRB in randomly growing cells. Given this, it is possible that a proportion of cells entered S phase because suciently high expression of the pRB mutant had not been reached upon transit of these cells through late G1. This might have allowed a spurious transcription of genes controlled by pRB at the G1/S restriction point, leading to accumulation of gene products sucient to begin DNA synthesis but insucient for full genome replication. To address whether phosphorylationdefective pRB can inhibit cell cycle progression in cells that have passed through the restriction point in late G1 we sought an experimental approach that would allow us to speci®cally induce expression of such pRB in cells that had already conducted a full G1 program.
To this end, we generated a construct expressing RB(NPC-) from a tetracycline (tet)-regulatable promoter. Identical to constitutively expressed pRB(NPC-), this tet-regulated construct when induced in a randomly growing population resulted in arrest of cells mostly in G1 with only a minor portion locked in S phase (Figure 5a ). To examine the eect of RB(NPC-) expression on cells that had passed the G1/S transition, we synchronised the transfected cell populations in early S phase by exposing them to the DNA synthesis inhibitor hydroxyurea before the induction of the phosphorylation-defective pRB. We found that upon release from the hydroxyurea block vector-transfected cells, and cells in which RB(NPC-) expression had not been induced, engaged in DNA synthesis, the vast majority of them completing replication of their entire genome within 18 h. In contrast, cells induced to express RB(NPC-) did not achieve this task even 24 h post release (Figure 5b) . In further experiments (data not shown) we found that completion of S phase was not achieved even 50 h later. We note that we observed consistently an increase in the DNA content in RB(NPC-) expressing cells occurring shortly after hydroxyurea release. This suggests that some degree of DNA synthesis may still occur, although these cells consistently failed to achieve Cell cycle phase-speci®c action of phosphorylationde®cient pRB(NPC-). (a) Induction of phosphorylation-de®cient pRB in asynchronously growing U2-OS cells. Cells were transiently transfected with pTRE-RB(NPC-), a plasmid encoding a tetracycline-inhibited activator protein (pTET-o) and pCMV-CD20. Expression of RB(NPC-) was induced 24 h post transfection (RB(NPC-) induced) by removal of tetracycline from the culture medium. Nocodazole was added 12 h following induction and cell cycle analysis was carried out 22 h later. Cells transfected with pTRE vector (vector) were treated identically. RB(NPC-) non induced' refers to cells in which pRB expression was repressed by the continuous presence of tetracycline in the culture medium. (b) Induction of phosphorylation-de®cient pRB in G1/S synchronized U2-OS cells. U2-OS cells were transfected as in (a), but were exposed to hydroxyurea 8 h post transfection to synchronize cells at the G1/S transition. Expression of RB(NPC-) was induced 24 h post transfection for a duration of 8 h. Cells were released from the hydroxyurea block and harvested for cell cycle analysis either immediately (t=0), 18 h (t=18) or 24 h (t=24) post hydroxyurea withdrawal full genome replication. We conclude that RB(NPC-) can block or at least substantially delay the completion of S phase and that it does so even in cells that completed G1/S transit.
Regulation of E2F by pRB phosphorylation site mutants
Recent evidence suggests that dierent phosphorylation sites may be responsible for regulating dierent types of pRB ligand interactions. Our previous experiments suggest that, likewise, transit through dierent cell cycle phases requires phosphorylation of dierent pRB sites. Together these two observations imply that regulation of distinct pRB/eector pathways might be responsible for regulating transit through the dierent cell cycle phases. To explore this possibility we investigated whether known G1/S eector pathways may be dierentially regulated by our dierent pRB phosphorylation site mutants. Various lines of evidence suggest involvement of the pRB/E2F pathway in controlling entry of cells into S phase (Johnson et al., 1993; Kowalik et al., 1995) . Furthermore, a recent report demonstrated that the binding of pRB to E2F can be regulated by phosphorylation of sites in the pRB pocket spacer (Knudsen and Wang, 1997) . Since the pocket spacer sites are mutated in RB(NPC-) but intact in RB(C-), these mutants may display a dierential ability to regulate E2F, this possibly accounting for the dierential ability to cause G1 arrest.
To address this, we examined the eects of these mutants on E2F-mediated promoter activation using a reporter construct driven by a synthetic promotor encompassing three E2F sites derived from the Adenovirus E2A promoter. We ®nd that RB(NPC-) suppresses transcription from this promoter substantially (see Figure 6 ). In contrast, the RB(C-) was considerably impaired in this respect. Notably, RB(C6-), the mutant lacking six instead of seven carboxy-terminal phosphorylation sites, repressed this promoter to a similar degree as RB(C-). Since RB(C6-) is signi®cantly weakened in its ability to inhibit cell cycle progression (see Figure 3b) , we conclude that partial repression of E2F activity by RB(C-) cannot be responsible for the lack of S phase completion seen in cells transfected with this mutant RB. To ensure that the eects observed were due to repression of E2F itself we used as a control a promoter in which the E2F sites were disabled for E2F binding by mutation (Bandara et al., 1993) . We ®nd that this mutant promoter was aected only marginally upon pRB cotransfection and, more importantly, that the dierent mutants permitted its transcription to a similar degree.
Results consistent with the above were also obtained with another reporter construct, driven by an upstream regulatory fragment of the Cyclin E promoter, which is known to mediate the regulation of this gene by E2F (Geng et al., 1996; Hurford et al., 1997) (Figure 6 ). In contrast, transcription driven by the SV40 immediate early enhancer, which does not contain E2F binding sites and is not in¯uenced by E2F expression (Geng et al., 1996) , was not dierentially regulated by the dierent pRB mutants.
Together our results demonstrate that RB(C-) and RB(NPC-) dier in their ability to suppress E2F-dependent gene activation. Furthermore, RB(C-) appears to allow a level of promotor activation similar to the mutant RB(C6-), that does not impair cell cycle progression. This strongly suggests that the S phase restraining function of RB(C-) may not operate through E2F but instead may be due to impacting on an RB eector independent thereof.
Eect of E2F-1 or cyclin E expression in RB(NPC-) expressing cells
Previous results suggest that ectopic expression of E2F or cyclin E, a downstream product critically regulated by the E2F pathway, are sucient to promote cell cycle progression in cells containing underphosphorylated, active pRB (Alevizopoulos et al., 1997; Johnson et al., 1993; Kowalik et al., 1995; Lukas et al., 1997) . However, if full cell cycle progression requires activation of an eector pathway independent of E2F, one would hypothesise that ectopic expression of E2F or cyclin E in the presence of RB(NPC-) should not allow progression into G2/M but instead should result in an accumulation of cells in S phase. To test this, we transfected expression constructs for either E2F-1 or cyclin E along with this phosphorylationdefective pRB (Figure 7) . We ®nd that coexpression of E2F-1 (Figure 7a) or cyclin E (Figure 7b ) with RB(NPC-) both drive the transfected cells into the S phase compartment. However, neither one appears to be sucient to trigger further cell cycle progression. This most directly supports a notion whereby the Figure 6 Eect of phosphorylation-defective pRB proteins on E2F-mediated promoter activation. U2-OS cells were transfected with luciferase reporter constructs linked to either three copies of an E2F binding sequence derived from the adenoviral E2A gene (3X wt-luc), three copies of a mutant sequence unable to bind E2F (3X mut-luc), the upstream regulatory region of the cyclin E gene (cyc E-luc) or the SV40 immediate early enhancer (SV40-luc). Luciferase values in cell extracts were determined upon cotransfection with dierent pRB constructs and plasmids encoding E2F-1 and DP-1. A CMV promoter-driven betagalactosidase gene was included to normalize for transfection eciency. Luciferase values were normalized to beta-galactosidase activity in the respective lysates and are represented as fold repression with respect to vector-transfected cells. Data shown are derived from at least three independent experiments observed inability to complete S phase is not related to an inability of cells to activate E2F-dependent gene transcription. We note that the inhibition of S phase completion seen in these experiments is not due to toxicity elicited by either E2F-1 or cyclin E since cells transfected with plasmid encoding E2F-1 or cyclin E alone advanced normally through the division cycle, achieving G2/M progression with an eciency similar to that of vector transfected cells (see Figure 7) .
Eect of adenoviral E1A oncoprotein on pRB mediated S phase progression
It has been long established that viral oncoproteins such as the adenoviral E1A or the SV40 large T antigen inactivate pRB's function by dissociating protein complexes between pRB and its cellular ligands.
To test whether the inhibition of S phase completion was sensitive to pRB-binding viral oncoproteins and thus may rely on association with an eector that can be displaced by these viral oncoproteins, we examined whether pRB's ability to restrict S phase progression was aected by the expression of adenoviral E1A. We found that expression of E1A resulted in full cell cycle progression when transfected with either RB(NPC-) alone or in conjunction with cyclin E and RB(NPC-) (Figure 8 ). In contrast, the E1A mutant pm928, which contains a point mutation in the CR2 domain and has a lowered anity for binding to pRB and other members of the pRB family (Abraham et al., 1992) , was strongly impaired in this respect.
These results imply that E1A apart from overcoming pRB's ability to inhibit S phase entry can also neutralise pRB's ability to inhibit S phase completion. They furthermore are congruent with the idea that pRB prevents S phase completion via interaction with eector proteins that can not bind to pRB in the presence of viral oncoproteins. Discussion pRB's role in controlling entry of cells into S phase is well established. Phosphorylation in late G1 lowers pRB's anity for transcription factors such as E2F, leading to activation of genes whose products are required to conduct DNA synthesis. The results presented here argue that in addition to inhibiting S phase entry, pRB can mediate growth control by undermining S phase completion.
How pRB operates to inhibit S phase completion is not conclusively answered by our analysis. Yet, various of our experiments point to the fact that control of S phase entry and control of S phase completion are separable events and could be mediated via distinct downstream eector pathways. For example, phosphorylation sites dissimilar from those regulating S phase entry appear to regulate S phase completion. Furthermore, ectopic expression of either E2F-1 of cyclin E, a gene controlled by the pRB/E2F pathway, is sucient to overcome inhibition of S phase entry, but does not overcome inhibition of S phase completion.
Other evidence suggests that the pRB controlled pathway(s) involved in inhibition of S phase comple- Figure 7 Eect of ectopically expressed E2F and cyclin E on the cell cycle progression of pRB(NPC-) expressing cells. U2-OS cells were cotransfected with vector or the phosphorylation-defective mutant RB(NPC-) and either pCMV or pCMV-E2F-1 (a) or RC-CMV or Rc-CMV-cyclin E (b). Cells were treated with nocodazole and cell cycle analysis was conducted as described for Figure 3 . DNA histograms shown are derived from one representative experiment. Results were con®rmed in three independent experiments Figure 8 Rescue of S phase entry and S phase progression by adenoviral E1A. U2-OS cells were transfected with RB(NPC-) alone or RB(NPC-) in combination with Cyclin E and plasmids encoding wt E1A or the pRB-binding defective E1A mutant pm928. Cell cycle analysis was carried out 48 h post transfection and following a 24 h treatment with nocodazole. Combinations of plasmids used are indicated on the top and the left hand site of the ®gure. DNA histograms shown are representative of three independent experiments tion and the pathway(s) controlling S phase entry have features in common. The adenoviral E1A oncoprotein neutralises both these activities. This suggests ®rstly, that pRB achieves inhibition of S phase completion by associating with cellular eectors whose binding can be obliterated via pRB-binding viral oncoproteins, and secondly, that control of both S phase completion and S phase entry are aected in cells expressing these viral oncoproteins.
Clues as to the operational mode by which pRB interferes with S phase completion would seem to come from our experiments examining the eect of phosphorylation-defective pRB in hydroxyureablocked cells. Upon release from this S phase block, these cells very obviously proceed to conduct DNA synthesis, yet fail to completely replicate their genome. It has been established that replication of a cell's genome occurs in steps, relying on subsequent and ordered activation of individual replicons (reviewed in Stillman, 1996) . Other evidence suggests that replicon initiation and DNA chain elongation are biochemically separable events (Gautschi et al., 1973; Iliakis, 1997; Stillman, 1996) . Our results could infer that chain elongation may continue in cells expressing phosphorylation-defective pRB but that activation of further replicons is no longer feasible. This in turn would suggest that pRB might interfere witht he origin activation machinery. It has been reported that pRB binds Pur-alpha, a single-strand DNA binding protein known to be involved in viral DNA replication (Johnson et al., 1995) . More recently, another protein associated with DNA replication, MCM7, has been isolated in a yeast based interaction screen using pRB as a bait (Sterner et al., 1998) . It is conceivable that pRB inhibits S phase completion by directly interacting with either one or both of these proteins. Alternatively, pRB might operate indirectly by inhibiting genes whose products are required for origin activation.
Our studies were based on the expression of phosphorylation-defective, and thus constitutively active pRB. A question that therefore must arise is, whether the ability of such mutant pRB to inhibit S phase completion is truly of physiological relevance. The answer to this question would seem to chie¯y depend on whether conditions exist that result in the accumulation of un-or partially phosphorylated pRB in cells that have passed the pRB phosphorylation point in late G1.
During the normal cellular division, pRB is un-or underphosphorylated only during the early phases of G1, becoming hyperphosphorylated in late G1 and this may inactivate its ability to inhibit S phase entry as well as S phase completion. However, there are a number of reports demonstrating that exposure of cells to stresses such as hypoxia or DNA-damaging agents results in the accumulation of underphosphorylated pRB, and that this occurs even when the cells have surpassed late G1, the point of time during which pRB phosphorylation is normally seen (Amellem et al., 1996; Haapajarvi et al., 1995; Linke et al., 1997) . The mechanisms by which such underphosphorylated pRB is produced have not been addressed in detail but could involve speci®cally inhibiting kinases that phosphorylate pRB during S phase. Alternatively, previously hyperphosphorylated pRB might be stripped of its phosphates by protein phosphatases.
Until now, evidence did not exist that underphosphorylated pRB is able to inhibit cell cycle progression once cells have passed through late G1. Our ®ndings, however, strongly argue that it can. Speci®cally, our results could indicate that pRB might operate to interfere with replicon activation rather than DNA chain elongation. It is intriguing that precisely this process is aected upon low dose radiation (Abraham et al., 1992; Iliakis, 1997) , which in turn suggests that pRB could play a role in executing this type of response.
Considering this, a further implication would seem to arise. If pRB indeed operates to prevent replicon activation upon DNA-damage, one would suspect that this procedure is impaired in tumours that lack pRB. This in turn would imply that an increased susceptibility to damage could arise in cells devoid of functional pRB. Increased damage susceptibility has long been suspected to be a key factor associated with tumour-causing genetic changes and may indeed be more suitable to explain the tumorigenic eects elicited by loss of pRB than is the lack of G1/S control suspected to arise from this condition.
Materials and methods
Plasmids and plasmid construction
A plasmid for expression of pRB in mammalian cells was constructed by inserting the human pRB coding sequence together with 12 residues of 5' untranslated region into the plasmid pEF-BOS (Mizushima and Nagata, 1990) . Mutation of serine 608 (S608) and threonine 826 (T826) into alanine have been described previously . All further serine/ threonine to alanine changes were performed using the QuickChangeTM site-directed mutagenesis kit (Stratagene). Mutagenesis was conducted using pBKS-RB(1 ± 928), a plasmid containing the pRB coding sequence inserted into the BamHI site of pBKS, as a template. Mutagenic primers used were as follows. Nucleotide changes resulting in substitution of threonine and serine residues into alanine are indicated in bold: S230A (ctattttattaaactcgcacctccatg and catgggaggtgcgagtttaataaaatag), S249A (ccattaatggtgcacctcgaacacc and ggtgttcgaggtgcaccattaatgg), T252A (gttcacctcgagcacccaggcg and cgcctgggtgctcgaggtgaac), T356A (gaaacacagagagcaccacgaaaaag and ctttttcgtggtgctctctgtgtttc), T373A (cctccacacgctccagttaggactg and cagtcctaactggagcgtgtggagg), S612A (ctcctgtaagagctccaaagaaaaaagg and ccttttttctttggagctcttacaggag), S780A (caggccccctaccttggcaccaatacc and ggtattggtgccaaggtagggggcctg), S788A (ctcacattcctcgagctccttacaag and cttgtaaggagctcgaggaatgtgag), S795A (caagtttcctagtgcacccttacgg and ccgtaagggtgcactaggaaacttg), S807A (ggaacatctatattgcacccctgaagag and ctccttcaggggtgcaatatagatgttcc), S811A (cacccctgaaggctccatataaaatttcag and ctgaaattttatatggagccttcaggggtg), and T821A (gaaggtctgccagcaccaacaaaaatgac and gtcatttttgttggtgctggcagaccttc). Serine and threonine residues were mutated sequentially to generate RB(N-), a mutant in which S230, S249, S252, T356, T373 were changed into alanines, RB(P-), a mutant with S608 and S612 changed into alanines, and RB(C-), a mutant with S780, S788, S795, S807, S811, T821, T826 changed into alanines. The mutated regions were fully sequenced and suitable fragments were isolated using restriction enzymes to replace corresponding sequences in pEF-BOS-RB(WT). Plasmids pEF-BOS-RB(NP-), pEF-BOS-RB(NC-), pEF-BOS-RB(PC-) and pEF-BOS-RB(NPC-) were then generated by combining pRB regions containing the appropriate mutations, as shown in Figure 1a .
To generate the tetracycline-regulatable RB(NPC-) expression construct, the reading frame of RB(NPC-) was ®rst inserted into pcDNA3 (9E10) (Ellis et al., submitted), resulting in a construct in which the pRB sequence is preceded by a 9E10 epitope tag and 60 residues of betaglobin 5' untranslated sequence. Following this, a fragment covering the beta-globin untranslated sequence, the 9E10 epitope-tag, and the pRB reading frame was inserted into pTRE (Clontech), a vector containing a tetracyclineregulatable promoter element. The plasmid pTet-o encoding a tet-regulated transcriptional repressor was purchased from Clontech.
Mammalian expression plasmids Rc-CMV-cyclin D1, Rc-CMV-cyclin E and Rc-CMV-cyclin A, encoding cyclin D1, cyclin E, and cyclin A respectively, have been described in Hinds et al. (1992) . Expression plasmids for E2F-1 (pCMV-E2F-1), DP1 (pCMV-DP1) and the surface marker CD20 (pCMV-CD20) were gifts of Xin Lu (Ludwig Institute, London) and have been described (Hsieh et al., 1997) . E2F reporter plasmids 3xE2F-luc and 3xmut-luc were a gift of R Watson (Ludwig Institute, London). They were generated by inserting a HindIII fragment containing either three copies of the E2F binding site from the Adenovirus E2A gene (3xE2F) or three copies of a non-E2F binding version thereof (3xE2Fmut) (Bandara et al., 1993) into the vector pGL2-basic (Promega). The cyclin E promoter plasmid (10-4 Cyclin E-luc) and the control vector (SV40-luc) was a gift of R Weinberg (Whitehead Institute, Cambridge, USA) and have been described (Geng et al., 1996) . Expression plasmids for E1A and the E1A mutant pm928 were provided by C Goding (Marie Curie, Oxted, UK) and have been described (Yavuzer et al., 1995) . pBABE-puro, a plasmid conferring puromycin resistance, has been described (Morgensternn and Land, 1990) .
Cell culture and transfection
The SAOS-2 osteosarcoma cell line was a gift from Xin Lu (Ludwig Institute, London). The C33-A cervical carcinoma cell line and the U2-OS osteosarcoma cell line were purchased from the American tissue culture collection. All cell lines were maintained in Dulbecco's Modi®ed Eagles Medium (DMEM) supplemented with 10% heatinactivated foetal calf serum (IFS) in a 5% CO 2 atmosphere. Transfections were performed using calcium phosphate-DNA coprecipitation (Bandara et al., 1993) .
Western blot analysis of phosphorylation-de®cient pRB C33-A cells were transfected with 10 mg pEF-BOS-RB(WT) or the various phosphorylation-site-de®cient pRB mutants and 3.3 mg each of Rc-CMV-cyclin D1, Rc-CMV-cyclin E, and Rc-CMV-cyclin A. Lysates were prepared 48 h post transfection in ELB buer (50 mM HEPES-NaOH, pH 7.0, 250 mM NaCl, 5 mM dithiothreitol (DTT), 10 mM NaF, 1 mM sodium vanadate, 10 mM beta-glycerol-phosphate, 2 mM phenylmethylsulphonyl¯uoride (PMSF), 18 mg/ml aprotenin and 2.5 mg/ml leupeptin). Lysate equivalent to 1/ 10th of a 10 cm dish was resolved on a 6% sodium dodecylsulphate (SDS)-polyacrylamide gel. Gels were transferred to Immobilon TM membrane (Millipore) and subjected to immunoblot analysis using anti-pRB antibody 14001a (Pharmingen) followed by an anti-mouse immunoglobulin secondary antibody coupled to horseradish peroxidase (Amersham). Immunocomplexes were detected by enhanced chemiluminescence (ECL) (Amersham).
Colony formation assay
U2-OS cells were transfected with 10 mg pEF-BOS-RB(WT) or the various pRB mutant constructs, 1 mg pBABE-Puro and 3 mg pcDNA-Gal. Transfected cultures were detached with trypsin 48 h post transfection. One half of each was seeded into two individual 10-cm dishes for colony assays and cultured in the presence of 1 mg/ml puromycin for 10 days. The remaining half was lysed in 250 mM Tris-HCl pH 7.8, 10% v/v glycerol and 1% v/v Triton X-100, and assayed for beta-galactosidase activity. To determine the number of puromycin-resistant colonies, dishes were treated with ®xative (4% formalin in PBS) for 10 min and stained with 1% crystal violet in 70% ethanol. Colony numbers in duplicate dishes were counted and their number normalised to the beta-galactosidase activity determined for the respective transfection to account for variations in transfection eciency.
Cell cycle analysis
Cells were transfected with 10 mg of pRB-encoding plasmid and 4 mg pCMV-CD20 plasmid, encoding a surface marker for detection of transfected cells. Where indicated, cells were treated with 400 ng/ml of the tubulin inhibitornocodazole, for 24 h prior to harvest. In experiments in which tetracycline-regulatable pRB constructs were used, cells were cultured and transfections performed in medium containing 2 mg/ml tetracycline. Cells were transfected with a mixture comprising 3 mg pTRE pRB and 15 mg pTET o and 4 mg CD20 surface marker. Transfected cultures were treated for 16 h with 5 mM hydroxyurea to synchronize cells at the G1/S border. To induce pRB expression the tetracycline-containing medium was replaced with medium without tetracycline, and cells were maintained in the presence of hydroxyurea for a further 8 h; after which time cell monolayers were washed twice with growth medium to remove hydroxyurea and cultured in medium containing nocodazole. For non-induced controls, tetracycline was present in the medium throughout the whole procedure.
To analyse the cell cycle position of transfected cells, cell monolayers were detached from the culture dishes using PBS containing 5 mM EDTA. Cells were collected by centrifugation and incubated with anti-CD20 antibody coupled tō uorescine-isothiocyanate (FITC) (Becton Dickinson). Subsequently cells were ®xed in 70% ethanol and stained with the DNA dye propidium iodide (PI) 0.04 mg/ml in the presence of 0.1 mg/ml`DNase-free' RNase A. The relative amount of PI¯uorescence associated with the CD20-positive cells in each sample was determined using a Becton Dickinson Immunocytometry System (BIDS) FACScan. Data for 5000 ± 10 000 CD20-positive cells were recorded per sample and analysed using the LYSYS II program software (Becton Dickinson).
Luciferase assays
Cells were transfected with 5 mg pRB expression plasmid, 5 mg Luciferase reporter construct (i.e. either 3xE2F-luc, 3xE2Fmut-luc, 10-4 E-luc or SV40-luc), 0.25 mg pCMV-DP-1, 0.1 mg pCMV-E2F1 and 2 mg pcDNA-gal. Cell monolayers were harvested 24 h post transfection and the luciferase activity present in individual samples were determined using the Promega luciferase assay kit. Values were normalized to beta-galactosidase activity present in the respective samples to account for variation in transfection eciency.
